Antioxidants for erectile dysfunction: a pooled benefit does not validate every blend
A 2025 meta-analysis found improved erectile-function scores across trials, but formulas, populations, and evidence quality varied.

Pooled antioxidant results are encouraging but do not identify one proven ingredient, dose, or retail blend for every man with ED.
Antioxidant is a broad research label
Antioxidant trials can test vitamins, minerals, amino-acid derivatives, plant extracts, or multi-ingredient formulas. These interventions differ in chemistry, dose, absorption, and intended mechanism. Pooling them can estimate whether the category shows a signal, but it cannot make each product interchangeable.
Erectile dysfunction also has multiple causes. Oxidative stress may be more relevant in some vascular or metabolic settings than in medication-related, neurologic, postsurgical, or psychological cases. An average across populations does not identify who should use which formula.

The 2025 meta-analysis found a favorable average
A systematic review and meta-analysis included 23 double-blind randomized placebo-controlled trials with 1,583 men. Across studies, antioxidant supplementation improved the erectile-function score by an adjusted mean of 5.5 points, with a larger modeled benefit in men with more severe symptoms. Reported side effects were uncommon and similar to placebo.
That is a meaningful research signal, not a retail recommendation. The pooled estimate combines different interventions and follow-up periods. It does not show that every antioxidant works, that ingredients can be substituted, or that a proprietary blend absent from the trials shares the average effect.
Severity findings need careful use
Meta-regression can explore whether study-level characteristics relate to effect size, but it is not the same as randomizing individual men by severity to a defined product. A seller should not market broadly to severe erectile dysfunction based solely on a pooled subgroup pattern.
Severe symptoms also raise the importance of clinical evaluation for underlying disease. A larger statistical effect does not justify delaying assessment or replacing established treatment. The cause and safety context still matter.

Safety pooling has limits
Short trials with selected participants may not capture uncommon interactions, long-term toxicity, or risks from different retail doses. A category-level side-effect rate cannot certify a product containing additional ingredients or contaminated material.
Consumers should inspect each ingredient, amount, medicine interaction, and product test. High-dose vitamins and minerals can cause harm despite the antioxidant label, and more antioxidant capacity is not a meaningful dosing target.
Translate the review into a research agenda
The next useful questions are which defined preparations produce clinically important responder rates, in which populations, for how long, and with what risks. Head-to-head and product-specific trials would be more actionable than another broad category average.
This guide does not recommend an antioxidant regimen. The review supports cautious interest and stronger trials. It does not establish that a shopper can select any antioxidant bottle and expect the pooled result. Marketing should name the tested intervention instead of borrowing credibility from the category.
Meta-analysis cannot repair weak blinding, selective reporting, or an unmatched placebo in the underlying studies. Heterogeneity matters when interventions range from vitamins to botanicals and complex formulas. A favorable average can coexist with null products and with a few unusually influential trials.
Readers should inspect risk-of-bias ratings, sensitivity analyses, heterogeneity, and which preparations drive the effect. Publication bias also matters because small favorable trials may appear more often than small null studies. A pooled number is only as dependable as the evidence entering it.
The mean score change does not reveal the chance that an individual using a particular product experiences a meaningful response. Responder thresholds, absolute group differences, confidence intervals, and product-specific results are needed. Without them, the meta-analysis supports a research signal rather than a shelf-wide recommendation.
The word antioxidant can also create a false impression that more is safer. High-dose vitamins, minerals, and plant extracts have distinct upper limits, medicine interactions, and toxicity profiles. A category-level safety average cannot cover an untested blend with additional ingredients. Product-specific risk review remains necessary even when pooled trials report few serious events.
The review should therefore guide trial design, not a shopping ranking. Researchers can identify promising preparations and test them directly against placebo and established care. Consumers need the name, composition, dose, population, duration, absolute effect, and uncertainty for the specific intervention. Without that detail, a pooled antioxidant claim is too broad to support a purchase or treatment decision.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.